Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.

Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H; MOVER Study Group.

Calcif Tissue Int. 2013 Aug;93(2):137-46. doi: 10.1007/s00223-013-9734-6. Epub 2013 May 5.

2.

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E.

Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review.

PMID:
19835464
3.

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.

Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H; MOVEST Study Group.

Osteoporos Int. 2015 Nov;26(11):2685-93. doi: 10.1007/s00198-015-3175-1. Epub 2015 May 23.

4.
5.

Ibandronate: A Review in Japanese Patients with Osteoporosis.

Keating GM.

Drugs Aging. 2016 Apr;33(4):295-303. doi: 10.1007/s40266-016-0360-7. Review.

PMID:
26915075
6.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

7.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.

JAMA. 1999 Oct 13;282(14):1344-52.

PMID:
10527181
8.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
9.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.

Osteoporos Int. 2013 Jan;24(1):293-9. doi: 10.1007/s00198-012-2056-0. Epub 2012 Jun 30.

10.

Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.

Sambrook P, Cranney A, Adachi JD.

Curr Med Res Opin. 2010 Mar;26(3):599-604. doi: 10.1185/03007990903512321.

PMID:
20055751
11.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR.

Curr Med Res Opin. 2005 Mar;21(3):391-401.

PMID:
15811208
12.

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators.

Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6.

PMID:
19362675
14.
15.

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.

Ito M, Tobinai M, Yoshida S, Hashimoto J, Nakamura T.

J Bone Miner Metab. 2017 Jan;35(1):58-64. doi: 10.1007/s00774-015-0723-x. Epub 2015 Nov 27.

PMID:
26614597
16.

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.

Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH.

Calcif Tissue Int. 2009 Nov;85(5):389-97. doi: 10.1007/s00223-009-9294-y. Epub 2009 Oct 9.

17.

Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

Hochberg MC.

Curr Osteoporos Rep. 2008 Sep;6(3):89-94. Review.

PMID:
18752769
18.

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.

Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.

J Bone Miner Res. 2009 Apr;24(4):719-25. doi: 10.1359/jbmr.081214.

19.

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.

Osteoporos Int. 2003 May;14(3):225-34. Epub 2003 Apr 10.

PMID:
12730746
20.

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D.

Osteoporos Int. 2012 Jun;23(6):1769-78. doi: 10.1007/s00198-011-1793-9.

PMID:
21975558

Supplemental Content

Support Center